Emergency AIDS relief
February 24, 2012
MYLAN Laboratories has received
tentative approval from the US
FDA under the President’s
Emergency Plan for AIDS Relief for
abacavir sulfate and lamivudine
tablets 60mg/30mg.
The fixed-dose combination
product was developed for use in
treating children with HIV/AIDS
and is based on the adult-strength,
brand version of Viiv Healthcare’s
Epzicom.
Mylan received tentative approval
for its adult-strength, generic
version of Epzicom in March 2009.
“The approval of abacavir sulfate
and lamivudine further supports
Mylan’s mission to continue
expanding access to high quality
medicine around the world, which
is especially crucial for children
living with HIV/AIDS,” said Mylan
CEO Heather Bresch.
“This product combines two
medications in one tablet, which
may support treatment adherence
in children as it reduces the pill
burden often associated with
complex antiretroviral regimens,”
she added.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Feb 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Feb 12
